Log In
BCIQ
Print this Print this
 

IMO-9200

  Manage Alerts
Collapse Summary General Information
Company Idera Pharmaceuticals Inc.
DescriptionToll-like receptor 7 (TLR7), TLR8 and TLR9 antagonist
Molecular Target Toll-like receptor 7 (TLR7) ; Toll-like receptor 8 (TLR8)
Mechanism of ActionToll-like receptor 8 (TLR8) antagonist; Toll-like receptor 7 (TLR7) antagonist; Toll-like receptor 9 (TLR9) antagonist
Therapeutic ModalityNucleic acid
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune diseases
Regulatory Designation
PartnerVivelix Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$207.5M

$15.0M

$192.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/28/2016

$207.5M

$15.0M

$192.5M

Get a free BioCentury trial today